- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| MERUS LABS Aktie jetzt für 0€ handeln |
0 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| MPH HEALTH CARE | 26,600 | +3,91 % | Dividendenbekanntmachungen (10.07.2026) | Unternehmen ISIN-Code Dividende (Währung) Dividende (EUR) ADVANCE AUTO PARTS INC US00751Y1064 0,25 USD 0,2187 EUR ALPHA BANK SA ADR US02071M5076 0,0187 USD 0,0163 EUR AMERICAN EAGLE OUTFITTERS... ► Artikel lesen | |
| EYEPOINT | 4,000 | +1,52 % | EyePoint drops as TD Cowen becomes latest to downgrade on late-stage trial setback | ||
| AMARIN | 11,700 | -0,85 % | Amarin Corporation plc: Amarin Highlights New REDUCE-IT and Mechanistic Data Presented at European Society of Cardiology (ESC) Congress 2026 | ||
| SELLAS LIFE SCIENCES | 12,000 | +0,42 % | Why Analysts Think Sellas Life Sciences Stock Can Gain 150% From Here | ||
| MADRIGAL PHARMACEUTICALS | 468,40 | +0,56 % | Madrigal Pharmaceuticals, Inc.: Madrigal Pharmaceuticals Reports Second-Quarter 2026 Financial Results and Provides Corporate Updates | Second-quarter 2026 Rezdiffra- (resmetirom) net sales of $364.3 million, representing year-over-year growth of 71% As of June 30, 2026, more than 49,000 patients on Rezdiffra, more than doubling... ► Artikel lesen | |
| CATALYST PHARMACEUTICALS | 27,300 | +2,63 % | Angelini Pharma Completes Acquisition of Catalyst Pharmaceuticals | The Italian pharma company grows its presence in the U.S. market and strengthens its global leadership in Brain Health and Rare DiseasesCompletion of the transaction gives Angelini Pharma ownership... ► Artikel lesen | |
| ANI PHARMACEUTICALS | 62,00 | +0,81 % | ANI Pharmaceuticals, Inc.: ANI Pharmaceuticals Appoints Henry Gosebruch to Board of Directors | - Appointment strengthens board as ANI accelerates transformation into a leading Rare Disease Company - PRINCETON, N.J., Aug. 24, 2026 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company)... ► Artikel lesen | |
| ELITE PHARMACEUTICALS | - | - | Elite Pharmaceuticals, Inc.: Elite Pharmaceuticals, Inc. Reports Financial Results for the First Quarter of Fiscal Year 2027 Ended June 30, 2026 and Provides Conference Call Information | Northvale, New Jersey--(Newsfile Corp. - August 13, 2026) - Elite Pharmaceuticals, Inc. (OTCQB: ELTP) ("Elite" or the "Company"), a specialty pharmaceutical company developing niche generic products... ► Artikel lesen | |
| DOGECOIN CASH | - | - | Dogecoin Cash, Inc.: Dogecoin Cash Files Utility Patent For Blockchain Infrastructure Designed To Support Dogecoin Application Usability | Mesquite, NV, June 15, 2026 (GLOBE NEWSWIRE) -- Mesquite, NV - June 15, 2026 - Dogecoin Cash, Inc. (OTC: DOGP) today announced the filing of a U.S. utility patent application with the United States... ► Artikel lesen | |
| BLUM HOLDINGS | - | - | BLUM HOLDINGS, INC. - 15-12G, Securities registration termination | ||
| THERIVA BIOLOGICS | 0,251 | 0,00 % | Theriva Biologics, Inc.: Theriva Biologics Reports Second Quarter 2026 Operational Highlights and Financial Results | - First patients dosed in the VIRAGE2 Phase 2a clinical study evaluating more frequent repeated dosing of VCN-01 (zabilugene almadenorepvec) the goal of which is to improve treatment outcomes in metastatic... ► Artikel lesen | |
| BMP PHARMA TRADING | 6,900 | 0,00 % | PTA-News: B.M.P. Pharma Trading AG: deutliche Steigerung der Rentabilität im 1. Halbjahr 2026 - Rentabilitätsanstieg EBIT um 52,9% | DJ PTA-News: B.M.P. Pharma Trading AG: deutliche Steigerung der Rentabilität im 1. Halbjahr 2026 - Rentabilitätsanstieg EBIT um 52,9%
Unternehmensmitteilung für den Kapitalmarkt
B.M.P. Pharma... ► Artikel lesen | |
| KAZIA THERAPEUTICS | 12,330 | +0,16 % | Kazia Therapeutics Limited: Kazia Therapeutics Reports Preclinical Data Showing Paxalisib Reprograms Immunotherapy-Resistant MSS/pMMR Colorectal Cancer and Enhances Response to Immunotherapy | Paxalisib Monotherapy Significantly Reduced Tumor Burden in Pre-Clinical Model of MSS/pMMR Colorectal Cancer, With the Addition of Pembrolizumab Driving a Further... ► Artikel lesen | |
| ALLERGY THERAPEUTICS | 0,050 | 0,00 % | Allergy Therapeutics - Trading update for the year ended 30 June 2026 | ||
| ACURA PHARMACEUTICALS | - | - | ACURA PHARMACEUTICALS, INC - NT 10-Q, Notification of inability to timely file Form 10-Q or 10-QSB |
MERUS LABS INTERNATIONAL INC gehört der Branche Pharma an.
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu MERUS LABS INTERNATIONAL INC finden Sie auf Wallstreet Online.